J Cancer 2018; 9(8):1486-1499. doi:10.7150/jca.23277
Cancer Stem Cells are Regulated by STAT3 Signalling in Wilms Tumour
1. School of Stomatology Lanzhou University, Lanzhou, Gansu Province, PR China
2. Department of Pediatric Surgery, The First Hospital of Lanzhou University, Lanzhou, Gansu Province, PR China
*These authors contributed equally to this work
Liu Y, Gao X, Wang S, Yuan X, pang Y, Chen J, Wang J. Cancer Stem Cells are Regulated by STAT3 Signalling in Wilms Tumour. J Cancer 2018; 9(8):1486-1499. doi:10.7150/jca.23277. Available from https://www.jcancer.org/v09p1486.htm
The survival rates associated with Wilms tumour (WT) remain dismal despite advancements in detection and treatment strategies. Cancer stem cells (CSCs) are correlated with the initiation, recurrence and metastasis of tumours, but its impact on Wilms cancer stem cell (WCSC) maintenance remains unclear. In this study, CD133+ cells were successfully isolated from a single-cell suspension of the G401 Wilms tumour cell line using magnetic activated cell sorting (MACS). Signal transducers and activators of transcription 3 (STAT3) has been implicated in tumorigenesis, but its contribution to the metastatic progression of WCSCs has not been investigated. Here, we show that STAT3 is overexpressed in WCSCs. Activation of STAT3 in WCSCs initiated a forward feedback loop that was responsible for mediating the aggressive malignant character of Wilms tumour cells in vitro and in vivo. Treatment of CD133+ cells with stattic, a STAT3 inhibitor, also inhibited tumour formation and progression in xenograft animal models in vivo. Collectively, these studies revealed a critical role of STAT3 signalling in WCSC proliferation and motility and a role for CD133 in cancer stem-like cell function, providing evidence for CD133 as a potential therapeutic target in Wilms tumour.
Keywords: Wilms Tumour, Cancer stem cells, STAT3, CD133